Despite a Phase IIb failure in diabetic neuropathy that prompted Sangamo BioSciences Inc. to drop lead drug SB-509, analysts believe earlier-stage programs may give the firm's zinc finger protein (ZFP) platform a better chance to shine. Read More
One place you wouldn't expect to hear debate about drug pricing is among the antibiotics experts gathered in Chicago this month for the 2011 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Antibiotics are, after all, about as cheap as a drug class can be. Read More
The Medicines Co. (MDCO), of Parsippany, N.J., settled lawsuits it filed relating to the abbreviated new drug applications (ANDA) filed by Teva Parenteral Medicines Inc., of Irvine, Calif., and Pliva Hrvatska doo, of Zagreb, Croatia, for generic versions of Angiomax (bivalirudin for injection). Read More
Patience paid off for Emergent BioSolutions Inc., which scored a big win on Monday by landing an award with the U.S. Centers for Disease Control and Prevention potentially worth $1.25 billion to supply the U.S. government with 44.75 million doses of BioThrax (anthrax vaccine adsorbed) over a five-year period. Read More
Santaris Pharma A/S, of Horsholm, Denmark, reported data from a Phase IIa trial showing that miravirsen, a microRNA-targeted drug, provided continuous and prolonged antiviral activity well beyond the end of active therapy in hepatitis C virus patients and was well tolerated. Read More